Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder.
Poor drug compliance caused by side effects is an important factor affecting clinical outcomes. Thus reliable and valid rating scales to accurately evaluate the side effects of medications in their early stages are needed. This study aimed to develop the Korean version of the Udvalg for Kliniske Undersøgelser (UKU) Side Effects Rating Scale for Patients (K-UKU-SERS-Pat) to comprehensively measure side effects of psychotropic medications by the self-report method and to examine reliability and validity in patients with bipolar disorder (BD). Ninety-three patients diagnosed with BD by DSM-IV criteria were recruited in this study. The patients completed the K-UKU-SERS-Pat. The Side Effects Rating Scale for Clinicians was administered simultaneously. In 19 patients, the K-UKU-SERS-Pat was conducted twice on a 3-day interval to examine the test-retest reliability. Depressive symptoms were evaluated with the Hamilton Depression Rating Scale-17 and (hypo)manic symptoms with the Young Mania Rating Scale. The test-retest reliability (rho=0.89, P<0.01) and the concurrent validity (rho=0.80, P<0.01) of K-UKU-SERS-Pat were good. However, patients had a tendency to report their side effects more frequently and severely than clinicians. The K-UKU-SERS-Pat is proved to be a reliable and valid tool to comprehensively and practically monitor the side effects of psychotropics.
Kim
Jeong-Hyun
JH
Mood Disorders Clinic and Clinical Affective Neuroscience Laboratory, Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea.
Choi
Sung-Won
SW
Joe
Soo Hyun
SH
Ha
Tae Hyon
TH
Yoo
Hee Jeong
HJ
Choi
Jung Eun
JE
Cha
Boseok
B
Ha
Kyooseob
K
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D018692:Antimanic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000208:ethnology / Q000523:psychology; D003431:Cross-Cultural Comparison; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007723:Korea; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D010349:Patient Compliance / Q000523:psychology; D017060:Patient Satisfaction; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011594:Psychometrics; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D015203:Reproducibility of Results; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000927:Anticonvulsants; D000928:Antidepressive Agents; D018692:Antimanic Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D016651:Lithium Carbonate; D014635:Valproic Acid